(20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an oxyalkanoic acid and camptothecin, which is are optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.
|
0. 106. A compound of the formula
##STR00017##
#6#
wherein R is R1—O(CH2)m—, m is an integer of 1-10 and R1 is
phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkylcarbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperazine, lower alkoxycarbonyl, and lower alkylcarbonylamino;
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
1- or 2-napthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
each of R2, R4, R5, and R6 is hydrogen; and
R3 is amino or nitro.
0. 90. A compound of the formula
##STR00015##
#6#
wherein R is R1—O-(CH2)m—, m is an integer of 1-10 and R1 is
phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperazino, lower alkoxycarbonyl, and lower alkylcarbonylamino;
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
1- or 2-naphthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
R2 is lower alkyl;
R3 is hydrogen;
R4 is hydroxy, lower alkoxy, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkylcarbonyl, carbamoyloxy, lower alkylcarbonyloxy;
R5 is hydrogen; and
R6 is hydrogen.
0. 123. A compound of the formula
##STR00019##
#6#
wherein R is R1—O-(CH2)m—, m is an integer of 1-10 and R1 is
phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkoxycarbonyloxy, benzyloxy, optionally substituted piperazino, lower alkoxycarbonyl, and lower alkylcarbonylamino;
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
1- 2-naphthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkyl, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
R2 is tri-lower alkylsilyl;
R3 is hydrogen;
R4 is hydroxy, lower alkoxy, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy;
R5 is hydrogen; and
R6 is hydrogen.
0. 72. A compound of the formula
##STR00013##
#6#
wherein R is R1—O-(CH2)m—, m is an integer of 1-10 and R1 is
phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperazino, lower alkoxycarbonyl, and lower alkylcarbonylamino;
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
1- or 2-naphthyl optionally substituted with from one to four substitutions independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
R2 is hydrogen, lower alkyl, or halogenated lower alkyl;
R3 is hydrogen or lower alkyl;
R4 is lower alkoxy, hydroxy, halogenated lower alkoxy, carbamoyloxy, lower alkylcarbonyloxy, or R4 together with R5 is methylenedioxy;
R5 is hydrogen, or together with R4 is methylenedioxy; and
R6 is hydrogen.
0. 55. A compound of the formula
##STR00011##
#6#
wherein R is R1—O—(CH2)m—, m is an integer of 1-10 and R1 is
#6# wherein R is R1—O-(CH2)m—, m is an integer of 1-10 and R1 is
phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperazino, lower alkoxycarbonyl, and lower alkylcarbonylamino;
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkylcarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
1- or 2-naphthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkyloxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkoxycarbonyloxy, and lower alkylcarbonylamino;
a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
R2 is hydrogen;
R3 is CH2NR7R8 (where each of R7 and R8 is independently H-, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R7 and R8 taken together with —N— represent a cyclic amino-), NR10R11 (where each of R10 and R11 is independently hydrogen, lower alkyl, phenyl, hydroxyl lower alkyl, amino lower alkyl, or mono- or di-lower alkyl, or R10 and R11 taken together with —N— represent a cyclic amino), or dialkylamino alkyl;
R4 is lower alkoxy, hydroxy, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, or R4 together with R5 is methylenedioxy;
R5 is hydrogen, or together with R4 is methylenedioxy; and
R6 is hydrogen.
phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperidino, lower alkoxycarbonyl, and lower alkylcarbonylamino;
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
1- or 2-naphthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
R2 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, RC(O)O (R is defined hereinbefore), cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, tri lower alkylsilyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkylcarbonyloxymethyl, substituted vinyl, 1-hydroxy-2-nitroethyl, alkoxycarbonylethyl, aminocarbonyl, mono- or di-alkylcarbonyl, alkylcarbonyloxymethyl alkylcarbonylmethyl, benzoylmethyl, benzylcarbonyloxymethyl, or mono- or di lower alkoxymethyl;
R3 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, RC(O)O (R is defined hereinbefore) cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hyroxycarbonyl, formyl, lower alkoxycarbonyl, CH2NR7R8 (where each of R7 and R8 is independently H-, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R7 and R8 taken together with —N— represent a cyclic amino-), CH2R9 (where R9 is lower alkoxy, CN, amino lower alkoxy, mono- or di-lower alkylamino lower alkoxy, lower alkylthio, amino lower alklthio, or mono- or di-lower alkylamino lower alkylthio), or NR10R11 (where each of R10 and R11 is independently hydrogen, lower alkyl, phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or di-lower alkyl, or R10 and R11 taken together with —N— represent a cyclic amino), dialkylamino alkyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino;
R4 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, RC(O)O (R is defined hereinbefore) cyano, nitro, amino, amino lower alkyl, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, or lower alkylcarbonylamino, or R4 together with R5 is methylenedioxy;
R5 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, RC(O)O (R is defined hereinbefore) cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino; and
R4 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, RC(O)O (R is defined hereinbefore) cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, or lower akylcarbonylamino.
2. The compound of
3. The compound of
4. The compound of
17. The compound of
18. The compound of
23. The compound of
25. The compound of
28. The compound of
29. The compound of
30. The compound of
34. The compound of
36. The compound of
38. The compound of
40. The compound of
41. The compound of
44. The compound of
45. A pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound as defined in
46. The pharmaceutical composition of
47. The pharmaceutical composition of
48. The pharmaceutical composition of
49. A method for treating cancer is a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound as defined in
53. A process of preparing a compound of
(a) a compound of the formula R—C(O)X, wherein R is R #6# 1—O—(CH2)m, R1 and m are defined as in
wherein
R3, R4, R5, and R6 are defined in
54. The process of
0. 56. The compound of
0. 57. The compound of
0. 58. The compound of
0. 59. The compound of
0. 60. The compound of
0. 61. The compound of
0. 62. The compound of
0. 63. The compound of
0. 64. A pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound as defined in #6# claim 55 in combination with a pharmaceutically acceptable excipient.
0. 65. The pharmaceutical composition of
0. 66. The pharmaceutical composition of
0. 67. The pharmaceutical composition of
0. 68. A method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound as defined in #6# claim 55.
0. 69. The method of
0. 70. The method of
0. 71. The method of
0. 73. The compound of
0. 74. The compound of
0. 75. The compound of
0. 76. The compound of
0. 77. The compound of
0. 78. The compound of
0. 79. The compound of
0. 80. The compound of
0. 81. The compound of
0. 82. A pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound as defined in #6# claim 75 in combination with a pharmaceutically acceptable excipient.
0. 83. The pharmaceutical composition of
0. 84. The pharmaceutical composition of
0. 85. The pharmaceutical composition of
0. 86. A method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound as defined in #6# claim 75.
0. 87. The method of
0. 88. The method of
0. 89. The method of
0. 91. The compound of
0. 92. The compound of
0. 93. The compound of
0. 94. The compound of
0. 95. The compound of
0. 96. The compound of
0. 97. The compound of
0. 98. A pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound as defined in
0. 99. The pharmaceutical composition of
0. 100. The pharmaceutical composition of
0. 101. The pharmaceutical composition of
0. 102. A method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound as defined in #6# claim 91.
0. 103. The method of
0. 104. The method of
0. 105. The method of
0. 107. The compound of
0. 108. The compound of
0. 109. The compound of
0. 110. The compound of
0. 111. The compound of
0. 112. The compound of
0. 113. The compound of
0. 114. The compound of
0. 115. A pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound as defined in #6# claim 106 in combination with a pharmaceutically acceptable excipient.
0. 116. The pharmaceutical composition of
0. 117. The pharmaceutical composition of
0. 118. The pharmaceutical composition of
0. 119. A method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound as defined in #6# claim 106.
0. 120. The method of
0. 121. The method of
0. 122. The method of
0. 124. The compound of
0. 125. The compound of
0. 126. The compound of
0. 127. The compound of
0. 128. The compound of
0. 129. The compound of
0. 130. The compound of
0. 131. A pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound as defined in #6# claim 124 in combination with a pharmaceutically acceptable excipient.
0. 132. The pharmaceutical composition of
0. 133. The pharmaceutical composition of
0. 134. The pharmaceutical composition of
0. 135. A method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound as defined in #6# claim 124.
0. 136. The method of
0. 137. The method of
0. 138. The method of
0. 139. A liposomal formulation that comprises a pharmaceutically acceptable liposome-forming material in combination with a compound of #6# claim 1.
0. 140. The liposomal formulation of
0. 141. The liposomal composition of
0. 142. The liposomal composition of
0. 143. The liposomal composition of
0. 144. The liposomal composition of
0. 145. The liposomal composition of
0. 146. The liposomal composition of
0. 147. A method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of the liposomal formulation as defined in #6# claim 139.
0. 148. The method of
0. 149. The method of
|
This application is a reissue of U.S. Pat. No. 6,350,756-B1 which claims priority to U.S. Provisional Application 60/263,040, filed Jan. 18, 2001, and is continuation-in-part thereof. This Provisional Application is incorporated herein reference.
Work regarding the invention described and claimed in this application was funded at least in part by a funding agreement with a Federal agency under chapter 18 of 35 U.S.C., namely Department of Defense grant DAMD 17-99-9018.
1. Field of the Invention
This invention relates to novel camptothecin derivatives that are useful for treating various types of cancer.
2. Background of the Invention
Camptothecin (often abbreviated as “CPT”), a phytotoxic alkaloid first isolated from the wood and bark of Camptotheca acuminata (Nyssaceae) by Wall and coworkers in 1966, was shown to have antitumor activity against the mouse leukemia L1210 system. The compound has a pentacyclic ring system with an asymmetric center in ring E with a 20 S configuration. The pentacyclic ring system includes a pyztolo [3, 4-b] quinoline (rings A, B and C), a conjugated pyridone ring D), and six membered lactone (ring E) with an 20-hydroxyl group. Camptothecin itself is essentially insoluble in water. Therefore, camptothecin was evaluated clinically as a water soluble sodium carboxylate salt in the early stages. It appears that the carboxylate salt was actually the compound where the E ring was open to form the sodium salt. This sodium salt produced severe toxicity and had very little in vivo anticancer activity. Thus early work on camptothecin was discontinued after starting phase II trials. However, interest in the compound revived when it was found to inhibit topoisomerase, an enzyme that is required for its swiveling and relaxation of DNA during molecular events such as replication and transcription. A number of syntheses and modifications of the molecule have been reported in the literature and new derivatives have been prepared over the years. For example, topotecan (9-dimethylaminomethyl-10-hydroxy CPT) and irinotecan (7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxy CPT) show clinical useful activity. This invention defines a new series of 20 S esters that are useful for treating various types of cancer. The novel compounds have higher potency and lower toxocity than CPT and other CPT derivatives.
One aspect of this invention is a compound of the formula (I), below,
##STR00001##
wherein R is R1—O—(CH2)m—, m is an integer of 1-10 (preferably 1-5); and R1 is
a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;
Another aspect of the invention is a pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound of the invention as defined herein in combination with a pharmaceutically acceptable excipient.
Another aspect of this invention is a method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound of the invention as defined herein. The compound is administered in a therapeutically effective dose by appropriate administration, e.g. orally, topically, or parenterally.
Another aspect of this invention is process for preparing compounds of this invention by reacting camptothecin (CPT) or a CPT analog with a compound of the formula R—C(O)X, where R is R1—O—(CH2)m, R1 is as defined herein, m is an integer of 1-10, and X is e.g. bromide, chloride, hydroxy, alkoxy of 1-11 carbons (e.g. —O(CH2)mCH3 where m is an integer of 1-10) or R—C(O)O—(R is defined hereinbefore).
Other aspects of this invention will be apparent to one of skill in the art by reviewing the ensuing specification.
Overview
In general this invention can be viewed as a (20S) ester of CPT or a CPT analog. As noted hereinbefore CPT is the (S) stereoisomer having a hydroxy at the 20 position. This hydroxy group is esterified in accordance with the process of this invention to form the corresponding (20S) ester in a stereospecific conversion in good yield. The resulting ester is unique in that has an electronegative entity in the chain, which is believed to aid in stabilizing the E ring of the camptothecin molecule. The novel compounds of the invention are active against tumors in mice and are generally well tolerated. They are usefull for treating various types of cancer and can be formulated to prepare pharmaceutical preparations for oral, topical, or parenteral administration.
While not wishing to be bound by any particular mechanism of action or theoretical explanation of how the compounds work, it is believed that the 20S esters exert their effect in part by stabilizing the E ring of the CPT molecule. The esters may accomplish this through steric hinderance by preventing enzymatic access to the E ring, through the presence of an electron-withdrawing group in the ester chain, i.e. an oxygen atom, and through facilitating the hydrogen-binding or Van Der Walls forces of the E ring end the CPT molecule with the enzyme to inhibit binding and thus enzyme activity to sever the E ring.
Definitions
The term “CPT” is an abbreviation for camptothecin, also known as (S)-4-ethyl-4-hydroxy-1H-pyrano-[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione. The compound is readily available from numerous sources, e.g., Sigma Chemical Co., St. Louis, Mo. The chemical formula of camptothecin and its numbering system are as follows:
##STR00002##
The compound has a hydroxy at the 20-position that is esterified to make the compounds of this invention.
The term “alkyl” refers to a monovalent, saturated aliphatic hydrocarbon radical having the indicated number of carbon atoms. For example, a “C 1-6 alkyl” or an “alkyl of 1-6 carbons” or “Alk 1-6” would refer to any alkyl group containing one to six carbons in the structure. “C 1-20 alkyl” refers to any alkyl group having one to twenty carbons. Alkyl may be a straight chain (i.e. linear) or a branched chain. Lower alkyl refers to an alkyl of 1-6 carbons. Representative examples lower alkyl radicals include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, isopentyl, amyl, sec-butyl, tert-butyl, tert-pentyl and the like. Higher alkyl refers to alkyls of seven carbons and above. These include n-heptyl, n-octyl, n-nonyl, n-decyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl, and the like, along with branched variations thereof. The radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and that do not significantly reduce the efficacy of the compounds. The alkyl is optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
The term “alkoxy” refers to a monovalent radical of the formula RO—, where R is an alkyl as defined herein. Lower alkoxy refers to an alkoxy of 1-6 carbon atoms, with higher alkoxy is an alkoxy of seven or more carbon atoms. Representative lower alkoxy radicals include methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, isopropoxy, isobutoxy, isopentyloxy, amyloxy, sec-butoxy, tert-butoxy, tert-pentyloxy, and the like. Higher alkoxy radicals include those corresponding to the higher alkyl radicals set forth herein. The radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and that do not significantly reduce the efficacy of the compounds. The alkyl is optionally substituted with one to five substituents independently selected from the group consisting of halo, lower akyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
The term “cycloalkyl” refers to a monovalent, alicyclic, saturated hydrocarbon radical having three or more carbons forming the ring. While known cycloalkyl compounds may have up to 30 or more carbon atoms, generally there will be three to seven carbons in the ring. The latter include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and that do not significantly reduce the efficacy of the compounds. The cycloalkyl is optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
The term “hydroxycarbonyl” is a monovolent radical having the formula —C(O)OH.
The term “lower alkoxycarbonyl” is a monovalent radical having the formula —C(O)OAlk, where Alk is lower alkyl.
The term “lower alkylcarboxyloxy” is a monovalent radical having the formula —OC(O)Alk, where Alk is lower alkyl.
The term “lower alkylcarbonylamino” is a monovalent radical having the formula —NHC(O)Alk, where Alk is lower alkyl.
A “halo” substituent is a monovalent halogen radical chosen from chloro, bromo, iodo, and fluoro. A “halogenated” compound is one substituted with one or more halo substituent.
A “1-naphthyl” or “2-naphthyl” is a radical formed by removal of a hydrogen from the 1- or 2-position of a naphthalene structure, respectively. It is optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, formyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
A “phenyl” is a radical formed by removal of a hydrogen from a benzene ring. The phenyl is optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperidino, lower alkoxycarbonyl, and lower alkylcarbonylamino.
A “cyclic amino” is a monovalent radical of a saturated 5-, 6-, or 7-membered cyclic amine ring having no more than one additional hetero atom such as nitrogen, oxygen, or sulfur. Representative examples include, e.g., 1-pyrrolidino, 1-piperidino, morpholino, piperazino, and the like. These may be substituted or unsubstituted. If substituted, generally they will have no more than 2 substituents chosen from lower alkyl, lower cycloalkyl, hydroxy lower alkyl, phenyl (substituted or unsubstituted), benzyl (substituted or unsubstituted), aminocarbonylmethyl, lower alkylaminocarbonylmethyl, amino, mono- or di-lower alkylamino, or cyclic amino.
A “carbamoyloxy” is a monovalent radical of the formula R13R14NC(O)O— (i.e. an aminocarbonyloxy) where R13 and R14 together form a cyclic amino with the nitrogen atom, or each of R13 and R14 is independently hydrogen, lower alkyl, hydroxy lower alkyl, hydroxy lower alkyl, amino lower alkyl, lower cycloalkyl, phenyl (substituted or unsubstituted), or benzyl (substituted or unsubstituted). Examples include aminocarbonyloxy, methylaminocarbonyloxy, dimethyl aminocarbonyloxy, [4-(1-piperidino)-1-piperidino]carbonyloxy, 1-morpholinocarbonyloxy, 1-pyrrolidinyl, 1-piperazinecarbonyloxy, and others delineated herein.
A “5-membered heterocyclic ring” is a monovalent radical of a 5-member closed ring containing carbon and at least one other element, generally nitrogen, oxygen, or sulfur and may be fully saturated, partially saturated, or unsaturated (i.e. aromatic in nature). Generally the heterocycle will contain no more than two hetero atoms. Representative examples of unsaturated 5-membered heterocycles with only one hetero atom include 2- or 3-pyrrolyl, 2- or 3-furanyl, and 2- or 3-thiophenyl. Corresponding partially saturated or fully saturated radicals include 3-pyrrolin-2-yl, 2- or 3-pyrrolidinyl, 2- or 3-tetrahydrofuranyl, and 2- or 3-tetrahydrothiophenyl. Representative unsaturated 5-membered heterocyclic radicals having two hetero atoms include imidazolyl, oxazolyl, thiazolyl, pyrazolyl, and the like. The corresponding fully saturated and partially saturated radicals are also included. The heterocyclic radical is bonded through an available carbon atom in the heterocyclic ring. The radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and that do not significantly reduce the efficacy of the compounds. The ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
A “6-membered heterocyclic ring” is a monovalent radical of a 6-member closed ring containing carbon and at least one other element, generally nitrogen, oxygen, or sulfur and may be fully saturated, partially saturated, or unsaturated (i.e. aromatic in nature). Generally the heterocycle will contain no more than two hetero atoms. Representative examples of unsaturated 6-membered heterocycles with only one hetero atom include 2-, 3-, or 4-pyridinyl, 2H-pyranyl, and 4H-pyranyl. Corresponding partially saturated or fully saturated radicals include 2-, 3-, or 4-piperidinyl, 2-, 3-, or 4-tetrahydropyranyl and the like. Representative unsaturated 6-membered heterocyclic radicals having two hetero atoms include 3- or 4-pyridazinyl, 2-, 4-, or 5-pyrimidinyl, 2-pyrazinyl, and the like. The corresponding fully saturated and partially saturated radicals are also included, e.g. 2-piperazine. The heterocyclic radical is bonded through an available carbon atom in the heterocyclic ring. The radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and that do not significantly reduce the efficacy of the compounds. The ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
A “fused 2-, 3-, or 4-ring heterocyclic radical” is polynuclear in that the adjacent rings share a pair of atoms, generally carbon atoms. At least one of the rings will be heterocyclic in that it will have a noncarbon atom such as nitrogen, oxygen, or sulfur. The ring system may contain from 9 to 18 atoms. A 2-ring heterocyclic system will generally have 9 to 10 atoms included in the ring. Examples of such a 2-ring system include quinoline, isoquinoline, purine, indolizine, 4H-quinolizine, 3H-pyrrolizine, coumaran, coumarin, isocoumarin, 4-methylcoumarin, 3-chloro-H-methylcoumarin, chromone, benzofuran, benzothiophene, benzothiazole, indole, and the like. A 3-ring system will generally have 12 to 14 atoms included in the ring. Examples of such a 3-ring system include carbazole, acridine, and the like. A 4-ring fused system will generally have 16 to 18 atoms included in the chain. Examples of such a 4-ring system include isothebaine and the like. The ring is bonded through a carbon in the ring system. The radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and that do not significantly reduce the efficacy of the compounds. The radical is optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino.
Other chemical terms are given their standard meaning as understood by one of skill in the art with guidance from standard texts and dictionaries.
The term “MTD” is the abbreviation for maximum tolerated dose.
The term “nM” is the abbreviation for nanomolar.
The term “ip” is the abbreviation for intraperitoneal.
One aspect of this invention is a compound of the formula
##STR00003##
wherein R is R1—O—(CH2)m—, m is an integer of 1-10 (preferably 1-5, particularly 1); and R1 is
A preferred aspect is a compound of formula (I) wherein m is 1, R1 is phenyl optionally substituted with one to three substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, and benzyloxy; and each of R2, R3, R4, R5, and R6 is H or R2—R6 are as described in the further discussion of preferred aspects as set forth hereinafter. In this subgroup, another preferred aspect is a compound wherein R1 is phenyl optionally substituted with one to three substituents independently selected from lower alkyl, halo, halogenated lower alkoxy, and lower alkoxy, particularly phenyl optionally substituted with one to three halo substituents. Also included are the pharmaceutically acceptable salts of these compounds. Pharmaceutically-acceptable salts are those salts formed by reacting an organic or inorganic acid with a compound represented by formula (I) where there is a reactive base (e.g., an available nitrogen). Suitable salts include, e.g., the acetate, hydrochloride, sulfate, phosphate, and the like. Others will be apparent to one of skill in the art by consulting standard sources such as Remington's mentioned herein.
Another preferred aspect is a compound wherein m is 1; each of R2 through R6 is H (or the preferences described hereinafter); and R1 is a fused, 2-ring heterocyclic system, e.g. a compound wherein R1 is represented by the formulas ##STR00004##
The names of these radicals are 2-benzothiazolyl, 3-chloro-4-methylcoumazin-7-yl, and 4-methylcoumarin-7-yl, respectively.
Another aspect is a compound of wherein m is 1: each of R2 through R6 is H (or the preferences discussed hereinafter); and R1 is 1- or 2-naphthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy and lower alkylcarbonylamino. Preferably R1 is 2-naphthyl.
Another aspect is a compound wherein m is 1, each of R2 through R6 is H (or the preferences described hereinafter), and R1 is 4-formylphenyl or ##STR00005##
The latter radical is named 4-[4-acetylpiperazin-1-yl)phenyl.
Another aspect is a compound wherein m is an integer of 2-4; each of R2 through R6 is H (or the preferences described hereinafter); and R1 is lower alkyl or phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, carbonyl, hydroxycarbonyl, lower alkoxycarbonyl, benzyloxy, lower alkylcarbonyloxy and lower alkylcarbonylamino.
One aspects of the invention include compounds as described hereinafter, but where R2, R3, R4, R5, and R6 each may be a substituent other than only hydrogen. These include, for example, the preferred subgroups set forth hereinafter:
The compound of formula (I), wherein R6 is hydrogen, particularly a compound wherein R4 and R5 together are methylenedioxy and wherein R2 is hydrogen. Of these the compounds particular interest are those where R3 is nitro, amino, methyl, chloro, cyano, acetoxy, or acetylamino.
A compound of formula (I), wherein each of R5 and R6 is hydrogen, especially those wherein R3 is hydrogen; R2 is (3-chloro-n-propyl)dimethylsilyl, tert-butyldimethylsilyl, acetoxymethyl, cyano, formylethenyl, ethoxycarbonylethenyl, cyanoethenyl, 2,2-dicyanoethenyl, (2-cyano-2-ethoxycarbony)ethenyl, ethoxycarbonylethyl, methyl, ethyl, or n-propyl; and R4 is hydroxy, acetoxy, amino, nitro, cyano, chloro, bromo, fluoro, lower alkyl, higher alkyl, lower alkoxy, carbamoyloxy, or formyl. Of these, the compounds wherein R2 is ethyl and R4 is carbamoyloxy are of further interest. Carbamoyloxy substituents that are preferred include 1-piperazinocarbonyloxy, 4-(i-propylaminocarbonylmethyl)piperazin-1-yl-carbonyloxy, or 4-(1-piperidino)-1-piperidinocarbonyloxy.
The compound of formula (I), wherein each of R2, R5, and R6 is hydrogen, for example, those wherein R3 is amino, nitro, cyano, halo, OH, lower alkylamino, di-lower alkylamino, lower alkyl, lower alkoxy, 1-piperidino, 1-mopholino, aminomethyl, lower alkylaminomethyl, cycloalkylaminomethyl, di-lower alylaminomethyl, cyclic aminomethyl, acetoxy, acetylamino, lower alkoxymethyl, omega hydroxy lower alkylaminomethyl, cyanomethyl and R4 is hydroxy, acetoxy, cyano, nitro, amino, halo, formyl, lower alkoxy, carbamoyloxy.
A compound wherein each of R2, R3, R5 and R6 is hydrogen and R4 is —OC(O)Alkyl1-20.
This aspect of the invention is a pharmaceutical composition useful for treating cancer in a warm-blooded animal, which composition comprises compound of the invention as defined herein in combination with a pharmaceutically acceptable excipient. The composition is prepared in accordance with known formulation techniques to provide a composition suitable for oral, topical, transdermal, rectal, by inhalation, parenteral (intravenous, intramuscular, or intraperitoneal) administration, and the like. Detailed guidance for preparing compositions of the invention are found by reference to the 18th or 19th Edition of Remington's Pharmaceutical. Sciences, Published by the Mack Publishing Co., Easton, Pa. 18040. The pertinent portions are incorporated herein by reference.
Unit doses or multiple dose forms are contemplated, each offering advantages in certain clinical settings. The unit dose would contain a predetermined quantity of active compound calculated to produce the desired effect(s) in the setting of treating cancer. The multiple dose form may be particularly useful when multiples of single doses, or fractional doses, are required to achieve the desired ends. Either of these dosing forms may have specifications that are dictated by or directly dependent upon the unique characteristic of the particular compound, the particular therapeutic effect to be achieved, and any limitations inherent in the art of preparing the particular compound for treatment of cancer.
A unit dose will contain a therapeutically effective amount sufficient to treat cancer in a subject and may contain from about 1.0 to 1000 mg of compound, for example about 50 to 500 mg.
The compound will preferably be administered orally in a suitable formulation as an ingestible tablet, a buccal tablet, capsule, caplet, elixir, suspension, syrup, trouche, wafer, lozenge, and the like. Generally, the most straightforward formulation is a tablet or capsule (individually or collectively designated as an “oral dosage unit”). Suitable formulations are prepared in accordance with a standard formulating techniques available that match the characteristics of the compound to the excipients available for formulating an appropriate composition. A tablet or capsule will contain about 50 to about 500 mg of a compound of Formula (I).
The form may deliver a compound rapidly or may be a sustained-release preparation. The compound may be enclosed in a hard or soft capsule, may be compressed into tablets, or may be incorporated with beverages, food or otherwise into the diet. The percentage of the final composition and the preparations may, of course, be varied and may conveniently range between 1 and 90% of the weight of the final form, e.g., tablet. The amount in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions according to the current invention are prepared so that an oral dosage unit form contains between about 5 to about 50% by weight (% w) in dosage units weighing between 50 and 1000 mg.
The suitable formulation of an oral dosage unit may also contain: a binder, such as gum tragacanth, acacia, corn starch, gelatin; sweetening agents such as lactose or sucrose; disintegrating agents such as corn starch, alginic acid and the like; a lubricant such as magnesium stearate; or flavoring such a peppermint, oil of wintergreen or the like. Various other material may be present as coating or to otherwise modify the physical form of the oral dosage unit. The oral dosage unit may be coated with shellac, a sugar or both. Syrup or elixir may contain the compound, sucrose as a sweetening agent, methyl and propylparabens as a perservative, a dye and flavoring. Any material utilized should be pharmaceutically-acceptable and substantially non-toxic. Details of the types of excipients useful may be found in the nineteenth edition of “Remington: The Science and Practice of Pharmacy,” Mack Printing Company, Easton, Pa. See particularly chapters 91-93 for a fuller discussion.
A compound may be administered parenterally, e.g., intravenously, intramuscularly, intravenously, subcutaneously, or interperitonically. The carrier or excipient or excipient mixture can be a solvent or a dispersive medium containing, for example, various polar or non-polar solvents, suitable mixtures thereof, or oils. As used herein “carrier” or “excipient” means a pharmaceutically acceptable carrier or excipient and includes any and all solvents, dispersive agents or media, coating(s), antimicrobial agents, iso/hypo/hypertonic agents, absorption-modifying agents, and the like. The use of such substances and the agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use in therapeutic compositions is contemplated. Moreover, other or supplementary active ingredients can also be incorporated into the final composition.
Solutions of the compound may be prepared in suitable diluents such as water, ethanol, glycerol, liquid polyethylene glycol(s), various oils, and/or mixtures thereof, and others known to those skilled in the art.
The pharmaceutical forms suitable for injectable use include sterile solutions, dispersions, emulsions, and sterile powders. The final form must be stable under conditions of manufacture and storage. Furthermore, the final pharmaceutical form must be protected against contamination and must, therefore, be able to inhibit the growth of microorganisms such as bacteria or fungi. A single intravenous or intraperitoneal dose can be administered. Alternatively, a slow long term infusion or multiple short term daily infusions may be utilized, typically lasting from 1 to 8 days. Alternate day or dosing once every several days may also be utilized.
Sterile, injectable solutions are prepared by incorporating a compound in the required amount into one or more appropriate solvents to which other ingredients, listed above or known to those skilled in the art, may be added as required. Sterile injectable solutions are prepared by incorporating the compound in the required amount in the appropriate solvent with various other ingredients as required. Sterilizing procedures, such as filtration, then follow. Typically, dispersions are made by incorporating the compound into a sterile vehicle which also contains the dispersion medium and the required other ingredients as indicated above. In the case of a sterile powder, the preferred methods include vacuum drying or freeze drying to which any required ingredients are added.
In all cases the final form, as noted, must be sterile and must also be able to pass readily through an injection device such as a hollow needle. The proper viscosity may be achieved and maintained by the proper choice of solvents or excipients. Moreover, the use of molecular or particulate coatings such as lecithin, the proper selection of particle size in dispersions, or the use of materials with surfactant properties may be utilized.
Prevention or inhibition of growth of microorganisms may be achieved through the addition of one or more antimicrobial agents such as chlorobutanol, ascorbic acid, parabens, thermerosal, or the like. It may also be preferable to include agents that alter the tonicity such as sugars or salts.
In some cases, e.g., where a compound of the invention is quite water insoluble, it may be useful to provide liposomal delivery. The system restrains the compound of the invention by incorporating, encapsulating, surrounding, or entrapping the compound of the invention in, on, or by lipid vesicles or liposomes, or by micelles.
Usefully, the compound of the invention is solubilized in liposomes. The liposomes may include, for example, lipids such as cholesterol, phospholipids, or micelles comprised of surfactant such as, for example, sodium dodecylsylfate, octylphenolpolyoxyethylene glycol, or sorbitan mono-oleate. Typically, the compound of the invention binds to the lipid bylayer membrane of the liposome with high affinity. The liposome bound prodrug can preferably intercalate between the acyl chains of the lipid. The lactone ring of the camptothecin-derivative, membrane-bound compound of the invention is thereby removed from the aqueous environment inside and outside of the liposome and further protected from hydrolysis. Since the liposome-bound drug is protected from hydrolysis, the antitumor activity of the drug is preserved. For a compound of the invention which has a lower affinity for the liposome membrane and thus disassociates from the liposome membrane to reside in the interior of liposome, the pH of the interior of the liposomes may be reduced thereby preventing hydrolysis of such compound of the invention.
A useful group of liposomal delivery systems which may be used in accordance with the present invention include those described in U.S. Pat. Nos. 5,552,156 and 5,736,156, which are herein incorporated in their entireties by reference. Other liposomal delivery systems which may be employed in accordance with the present invention include liposomes containing active agents aggregated with lipids or surfactants as described in U.S. Pat. Nos. 5,827,533 and 5,882,679; lipid vesicles formed with alkyl ammonium fatty acid salts as described in U.S. Pat. No. 5,874,105; liposomes for encapsulating active agent dry powder compositions as described in U.S. Pat. No. 5,783,211; liposomal drug delivery systems for topical patches as described in U.S. Pat. No. 5,718,914; the liposomes described in U.S. Pat. No. 5,631,237; the liposome and lipid complex compositions described in U.S. Pat. Nos. 5,549,910 and 5,077,057; the liposomes used for sustained release for steirodial drugs as described in U.S. Pat. No. 5,043,165; the liposomes described in U.S. Pat. No. 5,013,556; and the liposomes described in U.S. Pat. No. 4,663,161; all of which are herein incorporated in their entireties by reference.
Unilamellar liposomes, also referred to as single lamellar vesicles, are spherical vesicles comprised of one lipid bilayer membrane which defines a closed compartment. The bilayer membrane is composed of two layers of lipids; an inner layer and an outer layer. The outer layer of lipid molecules are oriented with their hydrophilic head portions toward the external aqueous environment and their hydrophobic tails pointed downward toward interior of the liposome. The inner layer of lipid lays directly beneath the outer layer; the lipids are oriented with their heads facing the aqueous interior of the liposome and their tails toward the tails of outer layer of lipid.
Multilamellar liposomes, also referred to as multilamellar vesicles, are composed of more than one lipid bilayer membrane, which membranes define more than one closed compartment. The membranes are concentrically arranged so that the different membranes are separated by compartments much like an onion skin.
Thus, some or all of the compound of the invention is located in one or more of the compartments of a liposome or micelle, or the compound of the invention is bound to the membrane of the liposome. Where a compound is bound to a lipid membrane, at least the lactone ring of some or all of the compound of the invention binds to the lipid membrane of the liposome, and where the liposome contains more than one bilayer membrane the compound of the invention is bound to at least 1 membrane. Those compounds of the invention that have a high affinity for such membrane tend to remain bound to the membrane. Those compounds of the invention with a low affinity for liposome membrane, will at least partially disassociate from the liposome membrane and reside in the liposome compartment.
Micelles as defined herein are spherical receptacles comprised of a single, monolayer membrane which defines a closed compartment and the membrane is comprised of surfactant molecules oriented so that the hydrocarbon tails are oriented toward the compartment and the polar head portions are oriented toward the external aqueous environment. The compounds of the invention, when associated with micelles, are either in the compartment, bound to the micelle membrane, or bound to the outside surface of the micelle.
Liposomes have been used successfully to administer medications to cancer patients, and have been shown to be useful clinically in the delivery of anticancer drugs such as doxorubicin, daunorubicin, and cisplatinum complexes. Forssen, et al., Cancer Res. 1992, 52: 3255-3261; Perex-Soler, et al., Cancer Res. 1990, 50: 4260-4266; and, Khokhar, et al., J. Med. Chem. 1991, 34: 325-329, all of which are incorporated herein in their entireties by reference.
Similarly, micelles have also been used to deliver medications to patients, (Broden et al., Acta Pharm Suec. 19: 267-284 (1982)) and micelles have been used as drug carriers and for targeted drug delivery, (D. D. Lasic, Nature 335: 279-280 (1992); and, Supersaxo et al., Pharm Res. 8: 1280-1291 (1991)), including cancer medications, (Fung et al., Biomater. Artif. Cells. Artif. Organs 16: 439 et seq. (1988); and Yokoyama et al., Cancer Res. 51: 3229-3236 (1991)), all of which are incorporated herein in their entireties by reference.
The liposomes and/or micelles containing the compound of the invention can be administered to a cancer patient, typically intravenously. The liposomes and/or micelles are carried by the circulatory system to the cancer cells where the membrane of the vesicle fuses to the membrane of the cancer cell thereby releasing the compound of the invention to the cancer cell, or where the liposomes and/or micelles to be taken up by the cancer cells, the compound of the invention diffuses from the liposomes and/or micelles to be taken up by the cancer cells.
Any lipid mixture of lipids which forms liposomes and/or micelles is suitable for use in the present invention. Phosphatidylcholines, including, for example, L-.alpha.-dimyristoylphosphatidylcholine (DPMC), 1-.alpha.-dipalmitoylphosphatidylcholine (DPPC) and L-.alpha.-distearoylphosphatidylcholine (DSPC) are suitable. Also, phosphatidylglycerols, including, for example, L-.alpha.-dimyristoylphosphatidylglycerol (DMPG) are suitable. The DMPC and DMPG are both fluid phase at 37, for example, L-.alpha.-dimyristoylphosphatidylglycerol (DMPG) are suitable. The DMPC and DMPG are both fluid phase at 37° C., while DSPC is solid phase at 37° C. Since the presence of negatively charged lipid in the liposome membrane causes the liposomes to repel each other, small amounts, such as, for example about 10%, of an negatively charged lipid, such as distearolphosphotidylglycerol (DSPG), may be incorporated in to the DSPC liposomes. Other suitable phospholipids include: phosphatidyl-ethanolamides, phosphatidylinositols, and phosphatidic acids containing lauric, myristic, palmitic, paimitoleic, stearic, oleic, linoleic, arachidonic, behenic and lignoceric acid. Another suitable lipid includes cholesterol.
U.S. Pat. No. 6,096,336 provides further guidance for preparing liposomal compositions useful in this invention and is incorporated herein by reference.
Another aspect of this invention is a method for treating cancer in a warm-blooded animal, which method comprises administering a therapeutically effective amount of a compound of the invention as defined herein. A compound useful in this invention is administered to an appropriate subject in need of these compounds in a therapeutically effective dose by a medically acceptable route of administration such as orally, parentally (e.g., intramuscularly, intravenously, subcutaneously, interperitoneally), transdermally, rectally, by inhalation and the like.
The term cancer is to be considered in the broadest general definition as a malignant neoplasm, an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of normal tissues and persists in the same excessive manner after cessation of the stimuli that evoked the change. It might be added that the abnormal mass is purposeless, preys on the host, and is virtually autonomous. A cancer can also be considered as a malignant tumor. A further discussion of neoplasia is found at “Robbins Pathologic Basis of Disease,” Sixth Edition, by R. S. Cotran, V. Kumar, and T. Collins, Chapter 8 (W. B. Saunders Company). This information from Chapter 8 is incorporated herein by reference. The following Table A provides examples of the types of cancers, i.e., malignant tumors or neoplasia that may be treated by administering a compound of this invention.
TABLE A
Tissue of Origin
Malignant
Composed of One Parenchymal
Cell Type
Mesenchymal tumors
Connective tissue and
Fibrosarcoma
derivatives
Liposarcoma
Chondrosarcoma
Osteogenic sarcoma
Endothelial and related
tissues
Blood vessels
Angiosarcoma
Lymph vessels
Lymphangiosarcoma
Synovium
Synovial sarcoma
Mesothelium
Mesothelioma
Brain coverings
Invasive meningioma
Blood cells and
related cells
Hematopoietic cells
Leukemias
Lymphoid tissue
Malignant lymphomas
Muscle
Smooth
Leiomyosarcoma
Straited
Rhabdomyosarcoma
Epthelial tumors
Stratified
Squarnous cell or
squarnous
epidermoid carcinoma
Basal cells of
Basal cell carcinoma
skin or odnexa
Epithelial lining
Glands or ducts
Adenocarcinoma
Papillary carcinoma
Cystadenocarcinoma
Respiratory passages
Bronchogenic carcinoma
Bronchial adenoma
(carcinoid)
Neuroectoderm
Malignant melanoma
Renal epithelium
Renal cell carcinoma
Liver cells
Hepatocellular carcinoma
Urinary tract epithelium
Transitional cell carcinoma
(transitional)
Placental epithelium
Choriocarcinoma
(trophoblast)
Testicular epithelium
Seminoma
(germ cells)
Embryonal carcinoma
More Than One Neoplastic Cell-
Mixed Tumors, Usually Derived
From One Germ Layer
Salivary glands
Malignant mixed tumor of
salivary gland origin
Breast
Malignant cystosarcoma
phyllodes
Renal anlage
Wilms tumor
More Than One Neoplastic Cell
Type Derived From More Than One
Germ Layer-Teratogenous
Totipotential cells in gonads or in
Immature teratoma, terato-
embryonic rests
carcinoma
The compounds of the invention are thus useful in the treatment of leukemia and solid tumors, such as colon, colo-rectal, ovarian, mammary, prostate, lung, kidney and also melanoma tumors. The dosage range adopted will depend on the route of administration and on the age, weight and condition of the patient being treated. The compounds may be administered, for example, by the parenteral route, for example, intramuscularly, intravenously or by bolus infusion.
As used herein, a “therapeutically effective amount” of CPT derivatives of the present invention is intended to mean that amount of the compound which will inhibit the growth of, or retard cancer, or kill malignant cells, and cause the regression and palliation of malignant tumors, i.e., reduce the volume or size of such tumors or eliminate the tumor entirely.
With mammals, including humans, the effective amounts can be administered on the basis of body surface area The interrelationship of dosages varies for animals of various sizes and species, and for humans (based on mg/m2 of body surface) is described by E. J. Freireichet al., Cancer Chemother. Rep., 50(4):219 (1966). Body surface area may be approximately determined from the height and weight of an individual (see, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y. pp. 537-538 (1970)). A suitable dose range is from 1 to 1000 mg of equivalent per m2 body surface area of a compound of the invention, for instance from 50 to 500 mg/m2.
For all of the administering routes, the exact timing of administration of the dosages can be varied to achieve optimal results. Generally, if using Intralipid 20 as the carrier for the CPT derivative, the actual dosage of CPT derivative reaching the patient will be less. This is due to some loss of the CPT derivative on the walls of the syringes, needles and preparation vessels, which is prevalent with the Intralipid 20 suspension. When a carrier, such as cottonseed oil is used, this above described loss is not so prevalent because the CPT derivative does not adhere as much to the surface of syringes, etc.
Another important feature of the method provided by the present invention relates to the relatively low apparent overall toxicity of the CPT derivatives administered in accordance with the teachings herein. Overall toxicity can be judged using various criteria. For example, loss of body weight in a subject over 10% of the initially recorded body weight (i.e., before treatment) can be considered as one sign of toxicity. In addition, loss of overall mobility and activity and signs of diarrhea or cystitis in a subject can also be interpreted as evidence of toxicity.
Another aspect of this invention is process for preparing compounds of this invention by reacting camptothecin (CPT) or a CPT analog with a compound of the formula R—C(O)X, wherein R is R1—O—(CH2)m, R1 is as defined herein, m is an integer of 1-10, and X is e.g. bromide, chloride, hydroxy, alkoxy of 1-11 carbons (e.g. —O(CH2)mCH3 where m is an integer of 1-10) or R—C(O)O—(R is defined hereinbefore). Preferably X is OH or lower alkoxy such as ethoxy. The compound shown as R1—O—(CH2)m—C(O)X can be referred to as an “oxyalkanoic acid” or an oxyalkanoic acid derivative.” One way that such an oxyalkanoic acid derivative is obtained is by reacting an appropriate alcohol (R1OH) with an omega-halogenated alkanoic acid or by reacting an arylalchohol (e.g. a phenol or substituted phenyl) with an omega-halogenated alkanoate, then hydrolyzing. Examples of such alkanoic acids include 2-bromoacetic acid, 3- bromopropanoic acid, 4-bromobutyric acid, 5-bromopentanoic acid, the corresponding alkyl esters (e.g., methyl, ethyl, propyl, and the like, preferably ethyl), the corresponding acid halides (especially the chloride), and the like. The ethyl ester of 2-bromoacetic acid is preferred. It may be useful to prepare an acid halide from the corresponding oxyalkanoic acid. The acid halides are obtained by reacting the corresponding oxyalkanoic acid with halogenated agents (such as SOCl2, PCl3, POCl3, PCl5, PBr3, and so on). The acid chloride is preferred. Once the oxyalkanoic acid or its derivative is prepared, it is reacted with CPT on a CPT analog to form the (S)-20-ester of CPT, i.e. compounds of this invention. This reaction sequence can be generalized as follows: ##STR00006##
In step 1 the reaction conditions will varying depending on the exact reactants employed. In general, solvents useful in the reaction may be aqueous or nonaqueous. Preferably, a solvent will be water, an organic solvent miscible with water, or mixtures thereof. Examples of useful miscible solvents include acetone and dimethyformamide (DMF). When the solvent is aqueous, the pH of the reaction will be basic, e.g. in the range of 10 to 14, preferably about 12 to 14. The reaction temperature vary with the reactant, and the solvents, and will range from about 20° C. to about 180° C., preferably about 40° C. to about 80° C. The time needed for the reaction to be complete will generally be no more than about 10 hours, preferably about 2 to 4 hours.
In step 2, the compound of formula (C) is converted to a compound of formula (D) by a hydrolysis reaction, generally performed in two stages. The reaction conditions for this step will vary in accordance with the compound being reacted. In general, solvents useful in the conversion may be aqueous or nonaqueous, preferably, a solvent will be water, either alone or with a water-miscible organic solvent. An example of a particularly useful solvent is a mixture of water and DMF or water and dioxane. The pH of the first stage of reaction will be basic, e.g. in the range of 10 to 14, preferably about 12 to 14. A suitable inorganic base such as an alkaline earth hydroxide, e.g. sodium hydroxide, is useful. The reaction temperature will range from about 0° C. to about 60° C., preferably about 20° C. to about 25° C. The time needed for the reaction to be complete will generally be no more than 10 hours, preferably no more than about 4 hours. The mixture is then acidified to a pH of less than 4, e.g. 3, with an appropriate acid such as hydrogen chloride and extracted with a suitable solvent such as ethyl acetate in accordance with standard chemical synthetic methods.
In step 2′, the compound of formula C (i.e. the oxyalkanoic acid is converted into the corresponding acid halide by reacting with a halogenated agent such as SOCl2, PCl3, POCl3, PCl5, and PBr3, and the like under appropriate conditions.
In step 3 of the process a compound of formula (D) is reacted with CPT or a CPT analog in about equimolar amounts under conditions suitable for the formation of the compounds of this invention as the 20-(S) stereoisomer. The reaction takes place in the presence of suitable carbodumide compoind such as diisopropylcarbodiimide, but preferably 1-(3-dimethylaminopropyl)-3-ethyl carbodiinide hydrochloride (EDCI), and 4-(dimethylamino) pyridine (DMAP) in the presence of a suitable solvent, preferably a nonaqueous, nonpolar solvent. Examples of usefull solvents in this step include halogenated alkanes, e.g., dichoromethane or trichloromethane) and DMF. Dichloromethane is particularly useful. The reaction temperature will range from about 20° C. to about 40° C., preferably about 20° C. to about 25° C. The time needed for the reaction to be complete will generally be no more than about 20 hours, preferably about 10 hours. It should be noted that a compound of formula (I) wherein one of R2-R6 is R1—O(CH2)m—C(O)O— along with R being R1—O(CH2)m is obtained by reacting a CPT analog where one of R2-R6 (particularly R4) is a hydroxy. In this case, the compound, e.g. the 10 hydroxy CPT, is reacted with 2 molar amount of the oxyalkanoic acid to give the disubstituted CPT derivative.
In step 1, suitable alcohols represented by formula (A) include the following:
One of skill in the art will recognize other representative alcohols with the guidance of this specification.
In step 2, suitable esters represented by formula (C) include the following:
One of skill in the art will recognize other representative esters with the guidance of this specification.
In step 3, a suitable CPT analog is a compound that is CPT substituted at the 7, 9, 10, 11, or 12 positions as described in this document. The CPT analog may be substituted with substituents known in the art or that can be prepared by one of skill in the art given the disclosure herein. Representative articles that teach how to make such analogs or where such analogs may be procured are found in the following journals (which are incorporated herein by reference):
Suitable CPT analogs include the following, where the number in parenthesis following the name refers to journal article listed above:
It will be recognized by one of skill in the art that other similar compounds may be prepared by following the teachings set forth in the above articles and modifying with appropriate art-recognized steps.
In step 3, suitable oxyalkanoic acids of formula (1) including the following:
One of skill in the art will recognize that other similar oxyalkanoic acids may be obtained from commercial sources or prepared by art-recognized procedures to be used in step 3 to prepare compounds of this invention. By reacting a compound shown in the list of CPT analogs with a compound shown in the list of compounds of formula (D) in accordance with the guidelines for reaction condition, compounds of the invention will be obtained. These compounds will exhibit the desired characteristics to a greater or lesser extent. Guidance is provided herein as to the preferred subgroups of compounds within the family.
The following examples are given to provide representative compounds included as part of this invention. The examples also provide descriptions of in vitro and in vivo assays to aid in determining the utility of the compounds. The camptothecin esters in examples 1-28 were prepared by the corresponding oxyacetic acid and camptothecin. Throughout the examples chemical formulas will be used to name compounds (e.g. NaHCO3 is sodium bicarbonate) as appropriate.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-fluorophenoxyacetic acid.
The mixture of camptothecin (30 mg, 0.086 mmol), 4-fluorophenoxyacetic acid (30 mg, 0.18 mmol), EDCI (60 mg, 0.31 mmol), DMAP (5 mg, 0.047 mmol) and dichloromethane (5 ml) was stirred at room temperature for 20 hours (h), then dichloromethane (20 ml) was added to the solution. The organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 33 mg camptothecin-20-O-4-fluorophenoxyacetate, yield: 76.7%, mp 227-229° C. (dec.).
The chemical structure analysis was performed by 1H NMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.25 (d, 1H, Ar—H), 7.96 (d, 1H, Ar—H), 7.86 (t, 1H, Ar—H), 7.69 (t, 1H, Ar—H), 7.19 (s, 1H, Ar—H), 6.97 (s, 2H, Ar—H), 6.88 (m, 2H, Ar—H), 5.68 (d, 1H, H17), 5.40 (d, 1H, H17), 5.29 (s, 2H, H5), 4.80 (q, 2H, OCH2CO), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-bromophenoxyacetic acid.
The mixture of camptothecin (30 mg, 0.086 mmol), 4-bromophenoxyacetic acid (41 mg, mmol), EDCI (60 mg, 0.31 mmol), DMAP (5 mg, 0.047 mmol) and dichloromethane (5 ml) was stirred at room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was recrystallized from ethyl acetate to afford 42 mg camptothecin-20-O-bromopbenoxyacetate, yield: 87.1%, mp 232-234° C. (dec.).
The chemical structure analysis was performed by 1H NMR (CDCl3, 600 MHz): δ 8.67 (s, 1H, Ar—H), 8.26 (d, 1H, Ar—H), 8.10 (d, 1H, Ar—H), 7.90 (t, 1H, Ar—H), 7.73 (t, 1H, Ar—H), 7.43 (d, 2H, Ar—H), 7.23 (s, 1H, Ar—H), 6.97 (d, 2H, Ar—H), 5.53 (d, 1H, H17), 5.45 (d, 1H, H17), 5.31 (s, 2H, H5), 5.15, 5.00 (dd, 2H, OCH2CO), 2.08 (d, 2H, CH2), 1.02 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-iodophenoxyacetic acid.
The mixture of camptothecin (30 mg, 0.086 mmol), 4-iodophenoxyacetic acid (36 mg, 0.18 mmol), EDCI (60 mg, 0.31 mmol), DMAP (5 mg, 0.047 mmol) and dichloromethane (5 ml) was stirred at room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 46 mg camptothecin-20-O-4-fluorophenoxyacetate, yield: 88.0%, mp 228-230° C.
The chemical structure analysis was performed by 1H NMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.29 (d, 1H, Ar—H), 7.98 (d, 1H, Ar—H), 7.88 (t, 1H, Ar—H), 7.70 (t, 1H, Ar—H), 7.56 (s, 2H, Ar—H), 7.22 (s, 1H, Ar—H), 6.71 (m, 2H, Ar—H), 5.68 (d, 1H, H17), 5.40 (d, 1H, H17), 5.29 (s, 2H, H5), 4.82 (q, 2H, OCH2CO), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-chlorophenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 4-chlorophenoxyacetic acid (12 mg, 0.064 mmol), EDCI (30 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12 mg camptothecin-20-O-4-chlorophenoxyacetate, yield: 80.0%, mp 199-202° C. (dec.).
The chemical structure analysis was performed by 1H NMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.25 (d, 1H, Ar—H), 7.96 (d, 1H, Ar—H), 7.86 (t, 1H, Ar—H), 7.69 (t, 1H, Ar—H), 7.19 (m, 3H, Ar—H), 6.85 (d, 2H, Ar—H), 5.68 (d, 1H, H17), 5.40 (d, 1H, H17), 5.29 (s, 2H, H5), 4.81 (q, 2H, OCH2CO), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 2,3-dichlorophenoxyacetic acid.
The mixture of camptothecin (30 mg, 0.086 mmol), 2,3-dichlorophenoxyacetic acid (42 mg, 0.18 mmol), EDCI (60 mg, 0.31 mmol), DMAP (5 mg, 0.047 mmol) and dichloromethane (5 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 41 mg camptothecin-20-O-2, 3-dichloroflurophenoxyacetate, yield: 86.5%, mp 238-239° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.25 (d, 1H, Ar—H), 7.96 (d, 1H, Ar—H), 7.86 (t, 1H, Ar—H), 7.69 (t, 1H, Ar—H), 7.21 (s, 1H, Ar—H), 7.14 (s, 1H, Ar—H), 7.10 (s, 1H, Ar—H), 6.85 (s, 1H, Ar—H), 5.68 (d, 1H, H17), 5.41 (d, 1H, H17), 5.29 (s, 2H, H5), 4.93 (q, 2H, OCH2CO), 2.25 (d, 2H, CH2), 0.98 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro-10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholinomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2imethylamino)ethyl CPT; and the like.
This example explains how to prepare non-subtituted and substituted camptothecin-20-O-estesr of 4-methoxyphenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 4-methoxyphenoxyacetic acid (11 mg, 0.060 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 13 mg camptothecin-20-O-4-methoxyphenoxyacetate, yield: 88.4%, mp 242-245° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.40 (s, 1H, Ar—H), 8.26 (d, 1H, Ar—H), 7.95 (d, 1H, Ar—H), 7.85 (t, 1H, Ar—H), 7.68 (t, 1H, Ar—H), 7.22 (s, 1H, Ar—H), 6.86 (t, 2H, Ar—H), 6.78 (d, 2H, Ar—H), 5.67 (d, 1H, H17), 5.43 (d, 1H, H17), 5.29 (s, 2H, H5), 4.78 (q, 2H, OCH2CO), 3.61 (s, 3H, OCH3), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
5-nitro-10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholinomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperdinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 2-nitrophenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 2-nitrophenoxyacetic acid (8.2 mg, 0.042 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 8.0 mg camptothecin-20-O-4-methoxyphenoxyacetate, yield: 52.3%, mp 232-234° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.26 (d, 1H, Ar—H), 7.95 (d, 2H, Ar—H), 7.85 (m, 2H, Ar—H), 7.69 (t, 1H, Ar—H), 7.55 (t, 1H, Ar—H), 7.20 (s, 1H, Ar—H), 7.08 (m, 2H, Ar—H), 5.86 (d, 1H, H17), 5.41 (d, 1H, H17), 5.29 (s, 2H, H5), 4.99 (q, 2H, OCH2CO), 2.25 (d, 2H, CH2), 0.98 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camnptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-]4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro-10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholinomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-amninocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-methylphenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 4-methylphenoxyacetic acid (10 mg, 0.63 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12.5 mg camptothecin-20-O-4-methylphenoxyacetate, yield: 88.0%, mp 229-233° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.42 (s, 1H, Ar—H), 8.28 (d, 1H, Ar—H), 8.20 (d, 2H, Ar—H), 7.96 (t, 1H, Ar—H), 7.72 (t, 1H, Ar—H), 7.19 (s, 1H, Ar—H), 7.02 (d, 2H, Ar—H), 5.71 (d, 1H, H17), 5.42 (d, 1H, H17), 5.30 (q, 2H, H5), 4.99 (q, 2H, OCH2CO), 3.61 (s, 3H, OCH3), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-]4-(1-piperidino]-1-piperidino)carbonoxyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro-10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholinomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-chloro-2-methylphenoxyacetic acid.
The mixture of camptothecin (30 mg, 0.086 mmol), 4-chloro-2-methylphenoxyacetic acid (30 mg, 0.15 mmol), EDCI (50 mg, 0.26 mmol), DMAP (5 mg, 0.05 mmol) and dichloromethane (4 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (20 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 32 mg camptothecin-20-O-4-chloro-2-methylphenoxyacetate, yield: 70.2%, mp 210-212° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41(s, 1H, Ar—H), 8.28 (d, 1H, Ar—H), 7.96 (d, 2H, Ar—H), 7.86 (t, 1H, Ar—H), 7.69 (t, 1H, Ar—H), 7.20 (s, 1H, Ar—H), 7.12 (d, 2H, Ar—H), 7.08 (s, 1H, Ar—H), 6.70 (d, 1H, Ar—H), 5.71 (d, 1H, H17), 5.42 (d, 1H, H17), 5.29 (q, 2H, H5), 4.85(q, 2H, OCH2CO), 2.23 (s, 3H, Ar—CH3), 2.20 (d, 2H, CH2), 0.98 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethysilyl CPT;
7-t-butyldimethysilyl-10-hydroxy CPT;
9-nitro-10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroethyl)aminomethyl-10-hydroxy CPT;
9-morpholinomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to explain to prepare non-substituted and substituted camptothecin-20-O-esters of 7-(carboxymethoxy)-3-chloro-4-methylcoumarin.
The mixture of camptothecin (10 mg, 0.029 mmol), 7-(carboxymethoxy)-3-chloro-4-methylcoumarin (11 mg, 0.042 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12 mg camptothecin-20-O-ester of 7-(carbonoxymethoxy)-3-chloro-4-methylcourmin, yield: 69.8%, mp 147-150° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.42 (s, 1H, Ar—H), 8.18 (d, 1H, Ar—H), 7.97 (d, 1H, Ar—H), 7.86 (t, 1H, Ar—H), 7.68 (t, 1H, Ar—H), 7.48 (d, 1H, Ar—H), 7.15 (s, 1H, Ar—H), 6.86 (t, 1H, Ar—H), 6.75 (s, 1H, Ar—H), 5.69 (d, 1H, H17), 5.43 (d, 1H, H17), 5.42 (s, 2H, H5), 4.90 (q, 2H, OCH2CO), 2.31 (s, 3H, ArCH3), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CTP;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 2-naphtoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 2-napthoxyacetic acid (8.5 mg, 0.042 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12.5 mg camptothecin-20-O-ester-2-napththoxyacetate, yield: 81.7%, mp 250-253° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.40 (s, 1H, Ar—H), 8.20 (d, 1H, Ar—H), 7.97 (d, 1H, Ar—H), 7.86 (t, 1H, Ar—H), 7.70 (m, 3 H, Ar—H), 7.20 (m, 6H, Ar—H), 5.69 (d, 1H, H17), 5.44 (d, 1H, H17), 5.25 (d, 2H, H5), 4.96 (s, 2H, OCH2CO), 2.25 (dm, 2H, CH2), 0.98 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CTP;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 3-bromomethylphenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 3-bromomethylphenoxyacetic acid (15 mg, 0.63 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12 mg camptothecin-20-O-3-bromomethylphenoxyacetate, yield: 72.7%, mp 226-228° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.24 (d, 1H, Ar—H), 7.95 (d, 2H, Ar—H), 7.86 (t, 1H, Ar—H), 7.69 (t, 1 H, Ar—H), 7.40 (d, 1H, Ar—H), 7.22 (s, 1H, Ar—H), 6.81 (s, 1H, Ar—H), 6.64 (d, 1H, Ar—H), 5.67 (d, 1H, H17), 5.43 (d, 1H, H17), 5.29 (s, 2H, H5), 4.80 (d, 2H, OCH2CO), 3.72 (s, 3H, Ar—CH2Br), 2.25 (d, 2H, CH2), 0.97 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CTP;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-benzloxyphenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 4-benzyloxyphenoxyacetic acid (16 mg, 0.063 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12 mg camptothecin-20-O-ester-4-benzyloxyphenoxyacetate, yield: 71.0%, mp 218-220° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.39 (s, 1H, Ar—H), 8.27 (d, 1H, Ar—H), 7.94 (d, 2H, Ar—H), 7.81 (t, 1H, Ar—H), 7.66 (t, 1 H, Ar—H), 7.32 (m, 6H, Ar—H), 6.87 (s, 4H, Ar—H), 5.68 (d, 1H, H17), 5.43 (d, 1H, H17), 5.29 (q, 2H5), 4.84 (q, 2H, OCH2CO), 4.79 (q, 2H, OCH2Ar), 2.25 (d, 2H, CH2), 0.98 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimeffiylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPr;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-isopropylphenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 4-isopropylphenoxyacetic acid (8 mg, 0.42 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12 mg camptothecin-20-O-4-isopropylphenoxyacetate, yield: 80.0%, mp 208-210° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.42 (s, 1H, Ar—H), 8.23 (d, 1H, Ar—H), 7.98 (d, 1H, Ar—H), 7.85 (t, 1H, Ar—H), 7.69 (t, 1 H, Ar—H), 7.10 (s, 2H, Ar—H), 6.84 (d, 2H, Ar—H), 5.63 (d, 1H, H17), 5.63 (d, 1H, H17), 5.25 (q, 2H, H5), 4.84 (q, 2H, OCH2CO), 2.72 (m, 1H, CHMe2), 2.21 (dm, 2H, CH2), 1.00 (m, 9H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CTP;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-formylphenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 4-formylphenoxyacetic acid (7.6 mg, 0.42 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 9.6 mg camptothecin-20-O-ester-4-formylphenoxyacetate, yield: 65.8%, mp 205-207° C.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 9.78 (s, 1H, CHO), 8.70 (s, 1H, Ar—H), 8.28 (d, 1H, Ar—H), 8.14 (d, 1H, Ar—H), 7.93 (t, 1 H, Ar—H), 7.89 (d, 2H, Ar—H), 7.75 (t, 1H, Ar—H), 7.20 (d, 2H, Ar—H), 5.58 (d, 1H, H17), 5.47 (d, 1H17), 5.33 (s, 2H, H5), 5.16 (d,2H,OCH2CO), 2.25 (m, 2H, CH2), 1.00 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 2,3,4,5,6-pentafluorophenoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), 2,3,4,5,6-pentafluorophenoxyacetic acid (10 mg, 0.042 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 5 mg camptothecin-20-O-2,3,4,5,6-pentafluorophenoxyacetate, yield: 30.5%, mp 210-213° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.23 (d, 1H, Ar—H), 7.97 (d, 2H, Ar—H), 7.85 (t, 1H, Ar—H), 7.68 (t, 1 H, Ar—H), 7.17 (d, 1H, Ar—H), 5.65 (d, 1H, H17), 5.40 (d, 1H, H17), 5.30 (s, 2H, H5), 4.99 (s, 2H, OCH2CO), 2.25 (d, 2H, CH2), 0.98 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CTP;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-carboxyphenoxyacetic acid.
The mixture of camptothecin (30 mg, 0.086 mmol), 4-carboxyphenoxyacetic acid (40 mg, 0.20 mmol), EDCI (65 mg, 0.34 mmol), DMAP (2 mg, 0.02 mmol), dichloromethane (2 ml) and DMF (2 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 7:3) to afford 27 mg camptothecin-20-O-ester-4-carbonoxyphenoxyacetate, yield: 59.6%, mp 243-245° C. (dec.).
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.29 (d, 1H, Ar—H), 8.03 (d, 2H, Ar—H), 7.96 (d, 1H, Ar—H), 7.86 (s, 1 H, Ar—H), 7.68 (s, 1H, Ar—H), 7.23 (s, 1H, Ar—H), 6.98 (d, 2H, Ar—H), 5.69 (d, 1H, H17), 5.41 (d, 1H, H17), 5.31 (q, 2H, H5), 4.92 (q, 2H, OCH2CO), 2.23 (d, 2H, CH2), 0.98 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of ethyloxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), ethyloxyacetic acid (10 mg, 0.10 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 10.5 mg camptothecin-20-O-ethyloxyacetate, yield: 84.7%, mp 238-240° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.40 (s, 1H, Ar—H), 8.22 (d, 1H, Ar—H), 7.95 (d, 2H, Ar—H), 7.84 (t, 1H, Ar—H), 7.68 (t, 1 H, Ar—H), 7.22 (s, 1H, Ar—H), 5.68 (d, 1H, H17), 5.44 (d, 1H, H17), 5.29 (q, 2H, OCH2), 4.29 (q, 2H, OCH2CO), 3.62 (m, 2H, OCH2), 2.25 (dm, 2H, CH2), 1.22 (t, 3H, CH3), 0.99 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CTP;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of butyloxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), butyloxyacetic acid (15.5 mg, 0.12 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 7:3) to afford 10 mg camptothecin-20-O-ester-butyloxyacetate, yield: 75.8%, mp 202-204° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.40 (s, 1H, Ar—H), 8.22 (d, 1H, Ar—H), 7.95 (d, 2H, Ar—H), 7.84 (t, 1H, Ar—H), 7.68 (t, 1 H, Ar—H), 7.22 (s, 1H, Ar—H), 5.68 (d, 1H), 5.44 (d, 1H), 5.29 (q, 2H, OCH2), 428 (q, 2H, OCH2CO), 3.53 (m, 2H, OCH2), 2.25 (dm, 2H, CH2), 1.57 (m, 2H, CH2), 1.36 (m, 2H, CH2), 0.98 (t, 3H, CH3), 0.88 (t, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of (−)-menthoxyacetic acid.
The mixture of camptothecin (10 mg, 0.029 mmol), (−)-menthoxyacetic acid (10.3 mg, 0.048 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 10.7 mg camptothecin-20-O-(−)-menthoxyacetate, yield: 68.6%, mp 1934-196° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.40 (s, 1H, Ar—H), 8.21 (d, 1H, Ar—H), 7.95 (d, 2H, Ar—H), 7.84 (t, 1H, Ar—H), 7.67 (t, 1 H, Ar—H), 7.22 (s, 1H, Ar—H), 5.70 (d, 1H, H17), 5.44 (d, 1H, H17), 5.29 (q, 2H, H5), 4.33 (q, 2H, OCH2CO), 3.20 (m, 1H, OCH), 2.40-2.00 (m, 4H), 2.00-0.60 (m, 19H).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
The camptothecin esters in examples 21-28 were prepared by first preparing the oxyacetic acid and then conducting the ester reaction.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 2,6-dichloro-4-fluorophenoxyacetic acid.
Synthesis of 2,6-dichloro-4-2,6-dichloro-4-fluorophenoxyacetic acid
The mixture of 2,6-dichloro-4-fluorophenol (362 mg, 2.0 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (500 mg, 3.0 mmol) and acetone (25 ml) was refluxed for 12 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 2, and then extracted three times with ethyl acetate (15 ml each). Organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was recrystallized from ethyl acetate and petroleum ether to give 348 mg 2,6-dichloro-4-fluorophenoxyacetic acid as white crystals, mp 155-158° C., yield: 72.8%.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 7.36 (m, 2H, Ar—H), 4.67 (s, 2H, OCH2CO).
Synthesis of Camptothecin-20-O-ester of 2,6-dichloro-4-fluorophenoxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), 2,6-dichloro-4-fluorophenoxyacetic acid (13 mg, 0.058 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 12.5 mg camptothecin-20-O-2,6-dichloro-4-fluorophenoxyacetate, yield: 76.7%, mp 201-204° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.24 (d, 1H, Ar—H), 7.96 (d, 2H, Ar—H), 7.85 (t, 1H, Ar—H), 7.70 (t, 1 H, Ar—H), 7.31 (s, 1H, Ar—H), 7.08 (d, 2H, Ar—H), 5.71 (d, 1H, H17), 5.45 (d, 1H, H17), 5.31 (s, 2H, H5), 4.82 (q, 2H, OCH2CO), 2.25 (dm, 2CH2), 1.02 (m, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for caniptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 3,4-methylenedioxyphenoxyacetic acid.
Synthesis of 3,4-methylenedioxyphenoxyacetic acid
The mixture of sesamol (270 mg, 2.0 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (2.55 ml, 22.9 mmol) and acetone (25 ml) was refluxed for 21 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 20 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the uiixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 2, and then extracted three times with ethyl acetate (20 ml each). Organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was recrystallized from chloroform and acetone to give 45 mg 3,4-methylenedioxyphenoxyacetic acid as white crystals, mp 149-151° C.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 6.74 (d, 1H, Ar—H), 6.57 (d, 1H, Ar—H), 6.40 (d, 1H, Ar—H), 4.63 (s, 2H, OCH2CO).
Synthesis of Camptothecin-20-O-ester of 3,4-methylenedioxyphenoxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), 3,4-methylenedioxyphenoxyacetic acid (8 mg, 0.042 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 8 mg camptothecin-20-O-3,4-methylenedioxyphenoxyacetate, yield: 53.0%, mp.
The chemical structure analysis was perfonned by 1HNMR (CD2Cl2, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.20 (d, 1H, Ar—H), 7.97 (d, 2H, Ar—H, 7.84 (t, 1H, Ar—H), 7.68 (t, 1 H, Ar—H), 7.17 (s, 1H, Ar—H), 6.68 (d, 2H, Ar—H), 6.53 (s, 1H, Ar—H), 6.34 (q, 1H, Ar—H), 5.83 (q, 2H, OCH2O), 5.63 (d, 1H), 5.39 (d, 1H), 5.26 (s, 2H, OCH2), 4.76 (q, 2H, OCH2CO), 2.25 (dm, 2H, CH2), 0.99 (m, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT; 30 9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy cPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 6-iodo-2-methylpyridine-5-oxyacetic acid.
Synthesis of 6-iodo-2-methylpyridine-5-oxyacetic acid
The mixture of 6-iodo-2-picolin-5-ol (235 mg, 1.0 mmol), potassium carbonate (455 mg, 3.3 mmol), ethyl bromoacetate (250 mg, 1.49 mmol) and acetone (15 ml) was refluxed for 15 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 3, and then extracted three times with ethyl acetate (20 ml each). Organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was recrystallized from ethanol and petroleum ether to give 165 mg 6-iodo-2-methylpyridine-5-oxyacetic acid as white crystals, mp 170-172° C.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 7.14 (s, 2Py-H), 4.83 (q, 2H, OCH2CO), 2.39 (s, 3H, CH3).
Synthesis of Camptothecin-20-O-ester of 6-iodo-2-methylpyridine-5-oxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), 6-iodo-2-methylpyridine-5-oxyacetic acid (18 mg, 0.063 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 14 mg camptothecin-20-O-6-iodo-2-methylpyridine-5-oxyacetate, yield: 78.7%, mp 231-233° C.
The chemical structure analysis was perfonned by 1HNMR (CD2Cl2, 600 MHz): δ 8.41 (s, 1H, Ar—H), 8.25 (d, 1H, Ar—H), 7.96 (d, 2H, Ar—H, 7.86 (t, 1H, Ar—H), 7.69 (t, 1 H, Ar—H), 7.27 (s, 1H, Ar—H), 7.02 (d, 1H, Ar—H), 6.97 (d, 1H, Ar—H), 5.68 (d, 1H, H17), 5.42 (d, 1H, H17), 5.30 (s, 2H, H5), 4.92 (q, 2H, OCH2CO), 2.43 (s, 3H, CH3), 2.25 (dm, 2H, CH2), 1.00 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of benzothiazole-2-oxyacetic acid.
Synthesis of benzothiazole-2-oxyacetic acid
The mixture of 2-benzothiazolol (320 mg, 2.1 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (500 mg, 3.0 mmol) and acetone (25 ml) was refluxed for 15 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with hydrochloric acid to pH 1, and then extracted three times with ethyl acetate (20 ml each). Organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was recrystallized from ethanol and petroleum ether to give 290 mg benzothiazole-2-oxyacetic acid as white crystals, mp 168-170° C.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 7.60 (s, 1Ar-H), 7.36 (s, 1H, Ar—H), 7.21 (s, 2H, Ar—H), 4.77 (q, 2H, OCH2CO).
Synthesis of Camptothecin-20-O-ester of benzothiazole-2-oxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), benzothiazole-2-oxyacetic acid (18 mg, 0.063 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 3 mg camptothecin-20-O-benzothiazole-2-oxyacetate, mp 186-189° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.39 (s, 1H, Ar—H), 8.28 (d, 1H, Ar—H), 7.93 (d, 2H, Ar—H, 7.84 (t, 1H, Ar—H), 7.68 (t, 1 H, Ar—H), 7.37 (d, 1H, Ar—H), 7.31 (s, 1H, Ar—H), 7.25 (s, 1H, Ar—H), 7.11 (t, 1H, Ar—H), 7.06 (d, 1H, Ar—H), 5.63 (d, 1H, H17), 5.39 (d, 1H, H17), 5.26 (s, 2H, H5), 4.90 (q, 2H, OCH2CO), 2.27 (dm, 2H, CH2), 0.97 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-cyano-3-fluorophenoxyacetic acid.
Synthesis of 4-cyano-3-fluorophenoxyacetic acid
The mixture of 2-fluoro-4-hydroxybenzonitrile (274 mg, 2.1 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (500 mg, 3.0 mmol) and acetone (25 ml) was refluxed for 6 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 1, and then extracted three times with ethyl acetate (20 ml each). Organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was recrystallized from ethanol and petroleum ether to give 268 mg 4-cyano-3-fluorophenoxyacetic acid as white crystals, mp 150-152° C.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 7.75 (m, 1Ar-H), 7.00 (m, 2H, Ar—H), 4.93 (s, 2H, OCH2CO).
Synthesis of Camptothecin-20-O-ester of 4-cyano-3-fluorophenoxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), 4cyano-3-fluorophenoxyacetic acid (12 mg, 0.062 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 14.9 mg camptothecin-20-O-4-cyano-3-fluorophenoxyacetate, yield: 98.7%, mp 238-240° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.43 (s, 1H, Ar—H), 8.23 (d, 1H, Ar—H), 7.96 (d, 1H, Ar—H), 7.87 (t, 1H, Ar—H), 7.70 (t, 1 H, Ar—H), 7.54 (t, 1H, Ar—H), 7.18 (s, 1H, Ar—H), 6.80 (m, 2H, Ar—H), 5.68 (d, 1H, H17), 5.42 (d, 1H, H17), 5.30 (q, 2H, H5), 4.91 (q, 2H, OCH2CO), 2.27 (dm, 2H, CH2), 0.99 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldim elsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy cPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of quinoline-4-oxyacetic acid
Synthesis of quinoline-4-oxyacetic acid
The mixture of 4-hydroxyquinoline (290 mg, 2.0 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (500 mg, 3.0 mmol) and acetone (25 ml) was refluxed for 8 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 3, and then extracted three times with ethyl acetate (20 ml each). Water layer was placed in cold room, and solid came out. The crystals were filtered with suction and washed with water, and then dried to give 120 mg quinoline-4-oxyacetic acid as gray crystals, mp 274-276° C.
The chemical structure analysis was performed by 1HNMR (DMSO-d6, 600 MHz): δ 8.17 (d, 1Ar-H), 7.94 (d, 1H, Ar—H), 7.69 (t, 1H, Ar—H), 7.46 (d, 1H, Ar—H), 7.38 (t, 1H, Ar—H), 6.08 (d, 1H, Ar—H), 5.08 (s, 2H, OCH2CO).
Synthesis of Camptothecin-20-O-ester of quinoline-4-oxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), quinoline-4-oxyacetic acid (12.8 mg, 0.063 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 5.9 mg camptothecin-20-O-quinoline-4-oxyacetate, yield: 38.6%, mp 258-260° C.
The chemical structure analysis was performed by 1HNMR (CD2Cl2, 600 MHz): δ 8.44 (s, 1H, Ar—H), 8.31 (t, 2H, Ar—H), 8.00 (d, 1H, Ar—H), 7.71 (m, 2H, Ar—H), 7.60 (b, 1 H, Ar—H), 7.37 (d, 1H, Ar—H), 7.28 (t, 1H, Ar—H), 7.15 (bs, 1H, Ar—H), 6.25 (bs, 1H, Ar—H), 5.59 (d, 1H, H17), 5.36 (d, 1H, H17), 5.25 (q, 2H, H5), 5.04 (q, 2H, OCH2CO), 2.27 (dm, 2H, CH2), 0.99 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare non-substituted and substituted camptothecin-20-O-esters of 4-nitro-3-trifluoromethylphenoxyacetic acid.
Synthesis of 4-nitro-3-trifluoromethylphenoxyacetic acid
The mixture of 4-nitro-3-trifluoromethylphenol (414 mg, 2.0 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (500 mg, 3.0 mmol) and acetone (25 ml) was refluxed for 8 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 2, and then extracted three times with ethyl acetate (20 ml each). Organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was separated by column chromatography (eluent: ethyl acetate: EtOH 9:1) to give 35 mg 4-nitro-3-trifluoromethylphenoxyacetic acid as white solid, mp 92-95° C.
The chemical structure analysis was performed by 1HNMR (DMSO-d6, 600 MHz): δ 8.15 (d, 1Ar-H), 7.46 (m, 2H, Ar—H), 5.03 (s, 2H, OCH2CO).
Synthesis of Camptothecin-20-O-ester of 4-nitro-3-trifluoromethylphenoxyacetic acid
The mixture of camptothecin (15 mg, 0.043 mmol), 4-nitro-3-trifluoromethylphenoxyacetic acid (20 mg, 0.075 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. Organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml) and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 17.1 mg camptothecin-20-O-4-nitro-3-trifluoromethylphenoxyacetic acid, yield: 66.8%, mp 207-209° C.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): δ 8.42 (s, 1H, Ar—H), 8.23 (d, 1H, Ar—H), 7.97 (m, 2H, Ar—H), 7.85 (t, 1H, Ar—H), 7.69 (t, 1 H, Ar—H), 7.35 (s, 1H, Ar—H), 7.21 (s, 1H, Ar—H), 7.15 (d, 1H, Ar—H), 5.69 (d, 1H, H17), 5.42 (d, 1H, H17), 5.30 (s, 2H, H5), 4.99 (q, 2H, OCH2CO), 2.27 (dm, 2H, CH2), 1.00 (s, 3H, CH3).
B. By substituting other camptothecin analogs for camnptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camnptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example explains how to prepare unsubstituted and substituted camptothecin-20-O-esters of estra-1,3,5(10)-trien-17-one-3-oxyacetic acid.
Synthesis of estra-1,3,5(10)-trien-17-one-3-oxyacetic acid
The mixture of estrone (540 mg, 2.0 mmol), potassium carbonate (910 mg, 6.6 mmol), ethyl bromoacetate (500 mg, 3.0 mmol), and acetone (25 ml) was refluxed for 6 h. After cooling, the mixture was filtered to remove potassium carbonate. The filtrate was concentrated under reduced pressure. To this residue, 10 ml dioxane and 14 ml 5% sodium hydroxide solution were added. After the mixture was stirred at room temperature overnight, it was acidified with concentrated hydrochloric acid to pH 2, and then extracted three times with ethyl acetate (15 ml each). The organic phases were combined, washed with water and brine, dried over magnesium sulfate, filtered, and then evaporated in vacuo. The residue was recrystallized from ethanol to give 246 mg estra-1,3,5(10)-trien-17-one-3-oxyacetic acid as white crystals, mp 205-208° C.
The chemical structure analysis was performed by 1HNMR (Acetone-d6, 600 MHz): δ 7.21 (d, 1Ar-H), 6.66 (d, 2H, Ar—H), 4.66 (s, 2H, OCH2CO), 2.50-1.40 (m, 15H), 0.90 (s, 3H, CH3).
Synthesis of Camptothecin-20-Oster of estra-1,3,5(10)-trien-17-one-3-oxyacetic acid
The mixture of camptothecin (10 mg, 0.029 mmol), estra-1,3,5(10)-trien-17-one-3-oxyacetic acid (20 mg, 0.061 mmol), EDCI (28 mg, 0.15 mmol), DMAP (2 mg, 0.02 mmol) and dichloromethane (3 ml) was stirred in the room temperature for 20 h, then dichloromethane (20 ml) was added to the solution. The organic layer was washed with water (20 ml), saturated NaHCO3 aqueous solution (10 ml), and brine (20 ml), and then dried over MgSO4. After the solvent was removed under reduced pressure, the resulting solid was separated by column chromatography (eluent: CHCl3:CH3OH 9:1) to afford 14.5 mg of camptothecin-20-O-2,6-dichloro-4-fluorophenoxyacetate, yield: 77.1%.
The chemical structure analysis was performed by 1HNMR (CDCl3, 600 MHz): 8.40(s, 1H, Ar—H), 8.24 (d, 1H, Ar—H), 7.95 (d, 2H, Ar—H), 7.85 (t, 1H, Ar—H), 7.70 (t, 1 H, Ar—H), 7.27 (s, 1H, Ar—H), 7.07 (d, 2H, Ar—H), 6.72 (t, 1H, Ar—H), 6.61 (d, 1H, Ar—H), 5.65 (d, 1H, ), 5.43 (d, 1H,), 5.29 (q, 2H, OCH2), 4.82 (q, 2H, OCH2CO), 2.80-0.83 (m, 21H).
B. By substituting other camptothecin analogs for camptothecin (CPT) in part A of this example other compounds of this invention are prepared. In naming camptothecin analogs, the standard numbering system for camptothecin will be employed with “CPT” being used as an abbreviation for camptothecin. Other camptothecin analogs include the following:
10,11-methylenedioxy CPT;
9-nitro CPT;
9-amino CPT;
9-amino-10-hydroxy CPT;
9-methylamino CPT;
9-dimethylamino CPT;
9-dimethylaminomethyl-10-hydroxy CPT (AKA topotecan);
9-piperidino CPT;
9-morpholino CPT
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy)-CPT (AKA irinotecan);
7-t-butyldimethylsilyl CPT;
7-t-butyldimethylsilyl-10-hydroxy CPT;
9-nitro 10,11-methylenedioxy CPT;
9-amino-10,11-methylenedioxy CPT;
9-methyl-10,11-methylenedioxy CPT;
9-chloro-10,11-methylenedioxy CPT;
9-cyano-10,11-methylenedioxy CPT;
9-acetyloxy-10,11-methylenedioxy CPT;
9-acetylamino-10,11-methylenedioxy CPT;
9-aminomethyl-10-hydroxy CPT;
9-methylaminomethyl-10-hydroxy CPT;
9-dimethylaminomethyl-10-hydroxy CPT;
9-(2-hydroxyethyl)aminomethyl-10-hydroxy CPT;
9-morpholiomethyl-10-hydroxy CPT;
7-ethyl-10-hydroxy CPT;
7-ethyl-10-acetyloxy CPT;
7-methyl-10-aminocarbonyloxy CPT;
7-n-propyl-10-piperidinocarbonyloxy CPT;
7-ethyl-10-(2-dimethylamino)ethyl CPT; and the like.
This example provides directions for growing cells and testing compounds of the invention for their effect on the growth of the cells. All cells were purchased from DCIDC Tumor Repository, NCI, NIH.
Cell Colony Formation Assay
Four hundred cells (HCT 116, PC-3, NCI/ADR-RES: human breast cancer cells) or five hundred cells (VM46) were plated in 60 mm Petri dishes containing 2.7 ml of medium (modified McCoy's 5a medium) containing 10% fetal bovine serum and 100 units/ml penicillin and 100 mg/ml streptomycin. The cells were incubated in a CO2 incubator at 37° C. for 5 hours for attachment to the bottom of Petri dishes. Drugs were made fresh in medium at ten times the final concentration, and then 0.3 ml of this stock solution was added to the 2.7 ml of medium in the dish. The cells were then incubated with drugs for 72 hours at 37° C. At the end of the incubation the drug-containing media were decanted, the dishes were rinsed with 4 ml of Hank's Balance Salt Solution (HBSS), 5 ml of fresh medium was added, and the dishes were returned to the incubator for colony formation. The cell colonies were counted using colony counter after incubation for 7 days for HCT116 cells and PC-3 cells and 8 days for VM46 cells, respectively. Cell survival (%) was calculated, as shown in Table I.
Values of ID50 (the drug concentration producing 50% inhibition of colony formation) may be determined for each tested compound. The directions described in this example may be used in other cells, such as DU-145.
TABLE I
This table provides results of in vitro efficacy tests performed
in example 29 for two cell lines: VM46 and PC-3.
In vitro efficacy: Survival (%) of cells line
Example
Compound
VM46
PC-3
No.
Name or No.
10 nM
1 nM
5 nM
1 nM
CPT
0
77.64
33.09
93.85
Taxol
70.82
80.59
41.36
82.80
1
000417
0
83.50
61.85
97.65
2
000315
0
64.37
22.24
87.38
3
000413
0
73.61
33.64
89.51
4
000517
5
000412
0
50.72
8.68
83.00
7
000411
0
76.87
33.09
90.09
8
000518
9
00127
0
47.33
31.46
88.97
10
000129
0
28.15
10.31
88.04
11
000224
0
62.69
37.98
87.34
12
000501
0
86.60
41.77
96.02
13
000425
0
80.46
71.61
99.28
14
000418
0
79.17
78.12
100
15
000313
0
41.58
21.16
89.51
16
000410
0
68.75
23.33
93.31
19
000316
0
77.50
54.79
85.72
20
0002031
0
74.84
69.44
100
21
000602
22
000419
0
75.46
43.94
88.43
000727
This example provides directions for performing in vivo toxicity tests of the compounds of the invention on C3H/HeJ mice.
Acute toxicities of the compounds of this invention are evaluated on C3H/HeJ mice (body weight 18-22 g). The MTD40 (maximum tolerated dose at day 40) values were determined by the standard procedure described by Gad and Chengelis (see, for example, “Acute Toxicology Testing,” 2nd Ed., Shayne O. Gad and Christopher P. Chengelis, pp. 186-195 (Academic Press)). In the consecutive type studies, 2 mice were dosed at low and moderate doses of 40 and 100 mg/kg. If no severe and irreversible toxicity (euthanasia is required) occurs at these doses, a new pair of animals was initiated at 180 mg/kg, which is 1.8 times higher than 100 mg/kg. Sequential dosages (about 3 doses on 3 pairs of animals, i.e. 2 mice for each drug dose) were increased by a factor of 1.8 until severe and irreversible toxicity (euthanasia is required) occurred. Then another pair of animals was initiated at the highest nonlethal dosage, and successive dosages were increased by a factor of 1.15. The result of this exercise was two dosages, one apparently nonlethal and the other lethal if severe and irreversible toxicity occurs and euthanasia is required, separated by a factor of 1.15. Six mice were dosed at each dosage. If no severe and irreversible toxicity occurred at the lower dosage and at least one with severe and irreversible toxicity occurred at the higher dose, then the lower dose was considered to be the MTD. The compounds of this invention were administered to C3H/HeJ mice by intraperitoneal injection. Drug toxicity was evaluated on mice checked daily for 45 days. The toxicity parameters reported are the MTD40, as shown in Table II, Example 31. The MTD is defined as the highest dose causing no severe irreversible toxicity in one treatment group, but at least one animal exhibiting severe and irreversible toxicity and being euthanized at the next higher dose.
This example provides directions for performing in vivo efficacy tests of the compounds of the invention on C3H/HeJ mice bearing MTG-B tumors.
Studies on the compounds of this invention were performed on C3H/HeJ mice bearing MTG-D tumors. The tumors grew exponentially following implantation into the flanks of the mice and reached a diameter of 8 mm (268.08 mm3) by day 7 to 10. Treatment was initiated at that time, with the first day of treatment designated as day 0 for calculation and plots. The mice were injected i.p. with thee drug dose levels (⅓, ½, 1×MTD) using both a single injection and the schedule of Q2D×3 (every 2 days for a total of 3 treatments at ⅓ MTD). Control groups of mice bearing 8 mm diameter tumors were treated with vehicle alone. After drug treatment, the mice were observed twice a day. When a tumor reached 1.5 g, the mouse bearing the tumor was euthanized. Surviving days measured from day 0 for mice treated with anticancer drugs (T) and surviving days measured from day 0 for control mice (C) were recorded. Tumor growth inhibition values (T/C %) were calculated using the formula T/C %=(surviving days of mice treated with an anticancer drug T/surviving days of control mice C)×100%, as shown in Table II.
Tumor sizes may be measured by caliper every day. Daily measurement (mm) of solid tumor (length L and width W) in two dimensions is used to calculate the tumor weight [tumor weight=(length×width2)/2] based on the interchangeable value of 1 mm3=1 mg. Tumor growth delay (T−C value) is determined by calculation of the median time (in days) required for the treatment group and control group tumors to reach 1,000 mg. Tumor doubting time (Td) is measured, and tumor cell kill is calculated by the formula of log cell kill=(T−C value)/(3.32×Td). Regression effects after treatment may be observed and recorded (a complete regression: a regression below limit of palpation; a partial regression: a regression of more than 50% reduction in tumor mass).
Table II provides results of the in vivo efficacy, in vivo toxicity, and in vivo efficacy tests performed in examples 29-30.
In Table II, the survival time of the control mice was six (6) days. The final right-hand column in Table II provides a ratio of the extra days of survival of mice treated with the compounds of the invention (compared to control) to the extra days of survival of mice treated with taxol (compared to control). For example, for compound 1, the mice survived 18 days as compared to 9 days for taxol-treated mice. The CD/Taxol ratio would be 18-6/9-6=12/3=4.
TABLE II
In Vivo Efficacy
T (Surviving days after
Compound
In Vitro Efficacy:
In Vivo Toxicity
treatment of MTG-B mouse
Code No.
Survival (%) of HCT116
MTD40 (ip, mg/kg)
mammary Adenocarcinoma
CD
(Example No.)
100 nM
10 nM
1 nM
in C3H/Hej Mice
In C3H/Hej mice
T/C %
CPT
—
73.72
100
<20**
—
—
—
CPT 11*
90.52
100
—
—
—
—
—
Taxol
0
0
86.40
40.6
9
150
—
000417 (1)
0
0
100
>150
18
300
4
000315 (2)
0
0
100
>150
18
300
4
000413 (3)
0
0
87.62
>150
18
300
4
000517 (4)
0
0
100
<150
—
000412 (5)
0
0
81.36
100
17
283
3.7
000314 (6)
0
>150
000411 (7)
0
0
95.13
>150
8
133
.7
000518 (8)
0
0
97.31
<150
000127 (9)
0
0
86.48
>150
13
217
2.3
000129 (10)
0
0
74.73
75
12
200
2.0
000224 (11)
0
0
100
>150
7
117
.3
000501 (12)
0
0
100
<150
000425 (13)
0
0
100
<150
000418 (14)
0
0
97.56
>150
000313 (15)
0
0
100
>150
9
150
1.0
000410 (16)
0
0
88.96
45
12
200
2.0
000725 (17)
0
0
100
>150
000627 (18)
0
0
70.44
<150
000316 (19)
0
0
100
<150
0002031 (20)
0
0
100
100
12
200
2.0
000602 (21)
0
0
74.00
>150
000419 (22)
0
0
100
45
12
200
2.0
000616 (23)
0
0
84.85
>150
001030 (25)
—
0
86.90
—
—
—
000727 (24)
0
0
96.81
—
—
—
000605 (27)
0
0
88.00
>150
000531 (28)
0
0
81.45
>150
—
—
—
*CPT 11 = Irinotecan
**Some literature sources indicate this number to be 12.
This example provides guidance for determining the hydrolysis kinetics of the lactone ring (E) of camptothecin derivatives in the presence of different blood components. A quantitative C18 reversed-phase high-performance liquid chromatography (HPLC) assay can be employed. A description is found at the following references:
This example provides guidance for determining the inhibition of topoisomerase I. This procedure is an intact cell assay and is a modification of a published procedure found at Cancer Res. 1986, 46, 2021-2026. A more recent publication can be found at J. Med. Chem. 1993, 36 2689-2700 at 2699. Here the modification of the previous procedure was used to quantitate the amount of topiosmerase I mediated DNA cleavage in intact cells. The DNA of HL-60 cells growing in culture in labeled by [3H] thymidine incorporation. The cells are exposed to compounds to be tested and lysed, and the protein is precipitated. Radioactive DNA in cleavable complex formation with topisomerase I co precipitates with the protein. The amount of cleavable complex formation is quantitated by counting the pellet with a liquid scintillation counter.
Yang, Li-Xi, Pan, Xiando, Wang, Huijan
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 4399282, | Jul 10 1979 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| 4943579, | Oct 06 1987 | UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Water soluble prodrugs of camptothecin |
| 5916896, | Jul 20 1994 | Research Triange Institute | Water-soluble esters of camptothecin compounds |
| 5965566, | Oct 20 1993 | ENZON, INC | High molecular weight polymer-based prodrugs |
| 6028078, | Aug 19 1996 | BioNumerik Pharmaceuticals, Inc. | Highly lipophilic camptothecin derivatives |
| 6040313, | Jul 20 1994 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
| 6057303, | Oct 20 1998 | BioNumerik Pharmaceuticals, Inc. | Highly lipophilic Camptothecin derivatives |
| 6096336, | Jan 30 1996 | The Christus Stehlin Foundation for Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 6113906, | Oct 27 1993 | Enzon, Inc. | Water-soluble non-antigenic polymer linkable to biologically active material |
| 6114529, | Oct 30 1996 | Tanabe Seiyaku Co., Ltd. | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
| 6120793, | Jan 30 1996 | The Christus Stehlin Foundation for Cancer Research | Methods of treating cancer using these derivatives |
| 6127355, | Oct 20 1993 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| 6153655, | Apr 17 1998 | ENZON, INC | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 6207832, | Apr 09 1999 | University of Kentucky Research Foundation | Camptothecin analogs and methods of preparation thereof |
| 6339091, | Jun 21 1995 | IPSEN PHARMA S A S | Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues |
| 6350756, | Jan 18 2001 | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | Camptothecin derivatives |
| 6403604, | Mar 01 2001 | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | Nitrogen-based camptothecin derivatives |
| EP861842, | |||
| WO66127, | |||
| WO67801, | |||
| WO3014069, | |||
| WO9510304, | |||
| WO9626950, | |||
| WO9719085, | |||
| WO9728165, | |||
| WO9813059, | |||
| WO9814459, | |||
| WO9828304, | |||
| WO9835940, | |||
| WO9851703, | |||
| WO9917805, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Feb 27 2001 | YANG, LI-XI | California Pacific Medical Center | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023692 | /0070 | |
| Feb 27 2001 | PAN, XIANDAO | California Pacific Medical Center | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023692 | /0070 | |
| Feb 27 2001 | WANG, HUIJUAN | California Pacific Medical Center | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023692 | /0070 | |
| Jul 31 2002 | California Pacific Medical Center | California Pacific Medical Center | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023692 | /0110 | |
| Jul 31 2002 | California Pacific Medical Center | Catholic Healthcare West | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023692 | /0110 | |
| Jan 16 2003 | Catholic Healthcare West | (assignment on the face of the patent) | / | |||
| Jan 16 2003 | California Pacific Medical Center | (assignment on the face of the patent) | / | |||
| Apr 24 2009 | California Pacific Medical Center | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 023180 | /0332 | |
| Apr 24 2009 | California Pacific Medical Center | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE S ADDRESS FROM 475 BRANNAN STREET, SUITE 200, SAN FRANCISCO, CA 94107 PREVIOUSLY RECORDED ON REEL 023180 FRAME 0332 ASSIGNOR S HEREBY CONFIRMS THE CORRECT ASSIGNEE S ADDRESS TO BE 475 BRANNAN STREET, SUITE 220, SAN FRANCISCO, CA 94107 | 023692 | /0030 |
| Date | Maintenance Fee Events |
| Aug 20 2009 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Jan 04 2010 | ASPN: Payor Number Assigned. |
| Jul 31 2013 | M2553: Payment of Maintenance Fee, 12th Yr, Small Entity. |
| Date | Maintenance Schedule |
| Jun 26 2010 | 4 years fee payment window open |
| Dec 26 2010 | 6 months grace period start (w surcharge) |
| Jun 26 2011 | patent expiry (for year 4) |
| Jun 26 2013 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jun 26 2014 | 8 years fee payment window open |
| Dec 26 2014 | 6 months grace period start (w surcharge) |
| Jun 26 2015 | patent expiry (for year 8) |
| Jun 26 2017 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jun 26 2018 | 12 years fee payment window open |
| Dec 26 2018 | 6 months grace period start (w surcharge) |
| Jun 26 2019 | patent expiry (for year 12) |
| Jun 26 2021 | 2 years to revive unintentionally abandoned end. (for year 12) |